BiotechTube
Home/Pipeline/Autoimmune Disease Therapies

Autoimmune Disease Therapies

Autoimmune Diseases

Pre-clinicalActive

Key Facts

Indication
Autoimmune Diseases
Phase
Pre-clinical
Status
Active
Company
Equaly

About Equaly

Equaly is an early-stage biotech leveraging a groundbreaking platform that targets antigen-specific innate immune cells to modulate immune responses. This approach has the potential to create novel vaccines, reduce immunogenicity of biological drugs, and develop curative therapies for autoimmune diseases. As a private, pre-revenue company likely in the pre-clinical stage, Equaly is positioned as a pioneer in a nascent field, seeking partnerships to advance its platform toward therapeutic applications.

View full company profile

Therapeutic Areas

OncologyInfectious DiseasesAutoimmune Diseases

Other Autoimmune Diseases Drugs

DrugCompanyPhase
Humira (Adalimumab) BiosimilarNeuCloneEarly Preclinical
HBM7020Harbour BioMedDiscovery
R2006Harbour BioMedDiscovery
R7027Harbour BioMedDiscovery
ImmCelz™ PlatformCreative Medical Technology HoldingsPreclinical
Not specified in provided content3SbioVarious
Gavocabtagene autoleucelastellasPhase 1/2
TYK-101TYK MedicinesPhase 1
HCB206HanchorBioPreclinical
miR-124 ActivatorFormation BioPhase 2
Autologous Cell Therapy CollaborationLupagenPreclinical
Autoimmune Diagnostics Leadership InitiativeVibrant America Clinical LaboratoryCommercial